| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 875 | 1,265 | 754 | 1,301 | 849 |
| Sales Growth | -30.79% | +67.73% | -42.05% | +53.19% | -27.31% |
| Net Income | -2,528 | -1,379 | -1,167 | -1,028 | -1,200 |
| Net Income Growth | -83.33% | -18.19% | -13.45% | +14.32% | -40.80% |
Rhelion Life Sciences Corp (RHEL.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Rhelion Life Sciences Corp is a pharmaceutical research and development company focused on the discovery and development of natural psychedelic medicines for psychiatric and neurological conditions.
Fiscal Year End Date: 03/31